Effectivity and Safety of Different Anticoagulants in Patients With Thromboembolic Antiphospholipid Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-01-01

Study Completion Date

2022-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Retrospective monocentric registry to evaluate the efficacy and safety of different anticoagulants in patients with thromboembolic antiphospholipid syndrome

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Monitoring Anticoagulant Therapy in Antiphospholipid Syndrome

NCT01660061

Antiphospholipid Syndrome

COMPLETED

Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS

NCT05646394

Antiphospholipid Syndrome Arterial Thrombosis

RECRUITING

Evaluation of an Antithrombotic Therapeutic Strategy in Pregnant Women

NCT00745212

Placental Vascular Pathologies Venous Thromboembolism Diseases

COMPLETED

OBServaToIre interNational Des Patients AnTiphospholipidEs traités Par Anticoagulants Oraux Directs

NCT06929182

Antiphospholipid Syndrome (APS) Direct Oral Anticoagulants (DOACs) Thrombotic and Bleeding Events +1 more

NOT_YET_RECRUITING

Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets

NCT05627375

Venous Thromboembolic Disease

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Antiphospholipid syndrome is a thrombophilic diathesis characterised by the occurrence of recurrent, unprovoked thromboembolic events (arterial, venous, microvascular) in combination with the presence of specific APS antibodies.

A distinction is made between different subtypes of APS. One is the thrombotic antiphospholipid syndrome (APS), which is the focus of the registry, and the other is obstetric APS, which is characterised by obstetric complications.

The particular challenge in dealing with APS patients is to establish an adequate therapy regime, as some patients suffer from an increased risk of recurrent thrombosis despite anticoagulation and/or aggregation inhibition.

The standard medication for antiphospholipid syndrome is based on the use of vitamin K antagonists (VKA). This regimen is essential to follow, especially in high-risk patients with positive lupus anticoagulants and/or triple positive antiphospholipid antibodies.

In 2019, a 'Red Hand Letter' was issued advising against treating APS patients with direct oral anticoagulants (DOACs) but so far some studies suggest that alternative anticoagulation with DOACs may be beneficial in a selected patient population with a single- or double-positive antiphospholipid antibody profile.

However, the current data on the use of DOAKs in patients with antiphospholipid syndrome is still limited. Therefore, the analysis of the patient data available in the investigator's specialised coagulation centre in the form of the APSantiCO registry should help to select a suitable anticoagulant regimen in everyday clinical practice.

The clinical and laboratory data required for the creation of the register are already available for evaluation in the form of electronic medical records, as the Coagulation Centre of the CCB Bethanien Hospital, which was founded in 2015, has been providing outpatient care to numerous APS patients for years. The data regarding the recording of recurrent thromboses despite anticoagulation and major bleeding under the various anticoagulants are collected with the help of a differentiated study of records. In addition, telephone contact is made with the patients. The telephone contact takes place within the framework of routine quality assurance in order to ensure optimal patient care, since many patients were unable or unwilling to attend their semi-annual or annual routine check-ups in the last two years due to the COVID 19 pandemic situation.

In the course of the telephone call, it should therefore be clarified whether a new appointment is needed, e.g. in case of a new event under the existing medication since the last presentation at the coagulation centre or in case of the occurrence of undesirable side effects and bleeding.

Apart from this telephone call, no patient contact is foreseen.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Antiphospholipid Syndrome Venous Thromboembolism Arterial Thromboembolism Major Bleed

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Minimum age of 18 years
* Confirmed antiphospholipid syndrome with thromboembolic clinical manifestations (VTE, LAE, stroke etc.)
* Patients with APS antibody risk profile (single/double/triple positivity)